{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:25Z","timestamp":1761895885864,"version":"3.40.4"},"reference-count":89,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T00:00:00Z","timestamp":1405641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"grants","award":["POSDRU\/159\/1.5\/G\/141531, PN 09.33\u201301.01\/2009, PN-II-ID-PCE-2011\u20132013\u20130918 and PN-II-RU-TE-2011\u20132013\u20132049"],"award-info":[{"award-number":["POSDRU\/159\/1.5\/G\/141531, PN 09.33\u201301.01\/2009, PN-II-ID-PCE-2011\u20132013\u20130918 and PN-II-RU-TE-2011\u20132013\u20132049"]}]},{"name":"post-doctoral fellowship","award":["POSDRU\/159\/1.5\/G\/141531"],"award-info":[{"award-number":["POSDRU\/159\/1.5\/G\/141531"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Biomark. Med."],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.2217\/bmm.14.76","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T10:22:22Z","timestamp":1405678942000},"page":"513-528","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":43,"title":["Proteomics Focusing on Immune Markers in Psoriatic Arthritis"],"prefix":"10.1080","volume":"9","author":[{"given":"Constantin","family":"Caruntu","sequence":"first","affiliation":[{"name":"Dermatology Research Laboratory,\u201cCarol Davila\u201d University of Medicine & Pharmacy, 2\u201324 Gr. Manolescu, 0111234, Sector 1, Bucharest, Romania"},{"name":"\u201cVictor Babes\u201d National Institute of Pathology, 99-101 Splaiul Independentei, 050096, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Boda","sequence":"additional","affiliation":[{"name":"Dermatology Research Laboratory,\u201cCarol Davila\u201d University of Medicine & Pharmacy, 2\u201324 Gr. Manolescu, 0111234, Sector 1, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgiana","family":"Dumitrascu","sequence":"additional","affiliation":[{"name":"\u201cVictor Babes\u201d National Institute of Pathology, 99-101 Splaiul Independentei, 050096, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Constantin","sequence":"additional","affiliation":[{"name":"\u201cVictor Babes\u201d National Institute of Pathology, 99-101 Splaiul Independentei, 050096, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Neagu","sequence":"additional","affiliation":[{"name":"\u201cVictor Babes\u201d National Institute of Pathology, 99-101 Splaiul Independentei, 050096, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,7,18]]},"reference":[{"key":"e_1_3_4_3_1","first-page":"176298","article-title":"Psoriatic arthritis: an update","author":"Lloyd P","year":"2012","unstructured":"Lloyd P , RyanC, MenterA. Psoriatic arthritis: an update. Arthritis176298 (2012).","journal-title":"Arthritis"},{"issue":"2","key":"e_1_3_4_4_1","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman DD","year":"2005","unstructured":"Gladman DD , AntoniC, MeasePet al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis.64(Suppl. 2), ii14\u201317 (2005).","journal-title":"Ann. Rheum. Dis."},{"issue":"89","key":"e_1_3_4_5_1","first-page":"65","article-title":"Soluble biomarkers may differentiate psoriasis from psoriatic arthritis","volume":"39","author":"Chandran V.","year":"2012","unstructured":"Chandran V. Soluble biomarkers may differentiate psoriasis from psoriatic arthritis. J. Rheumatol.39(89), 65\u201366 (2012).","journal-title":"J. Rheumatol."},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00372065"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318986"},{"issue":"5","key":"e_1_3_4_8_1","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni CE","year":"2008","unstructured":"Antoni CE , KavanaughA, van der HeijdeDet al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J. Rheumatol.35(5), 869\u2013876 (2008).","journal-title":"J. Rheumatol."},{"key":"e_1_3_4_9_1","first-page":"65","article-title":"Detecting psoriasis arthritis early in the disease course \u2013 why this is important and how dermatologists and rheumatologists can successfully cooperate?","author":"H\u00e4rle P.","year":"2012","unstructured":"H\u00e4rle P. Detecting psoriasis arthritis early in the disease course \u2013 why this is important and how dermatologists and rheumatologists can successfully cooperate? In: Psoriasis.SoungJ (Ed.). 65\u201378 (2012).","journal-title":"Psoriasis."},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3261"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03363.x"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1117\/1.JBO.17.8.085003"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20575"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.55631"},{"key":"e_1_3_4_16_1","first-page":"85","article-title":"Studiu Privind Eficacitatea Terapiei Fotodinamice Cu Acid 5-Aminolevulinic in Psoriazis Vulgar","volume":"53","author":"Boda D","year":"2008","unstructured":"Boda D , DiaconeasaA, NeaguMet al. Studiu Privind Eficacitatea Terapiei Fotodinamice Cu Acid 5-Aminolevulinic in Psoriazis Vulgar. Dermatovenerol. (Buc.)53, 85\u201390 (2008).","journal-title":"Dermatovenerol. (Buc.)"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201617"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130455"},{"issue":"5","key":"e_1_3_4_19_1","first-page":"665","article-title":"Differential expression of proteins with heparin affinity in patients with rheumatoid and psoriatic arthritis: a preliminary study","volume":"31","author":"Grazio S","year":"2013","unstructured":"Grazio S , RazdorovG, ErjavecIet al. Differential expression of proteins with heparin affinity in patients with rheumatoid and psoriatic arthritis: a preliminary study. Clin. Exp. Rheumatol.31(5), 665\u2013671 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3383"},{"key":"e_1_3_4_21_1","first-page":"474028","article-title":"Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris","author":"Dalmady S","year":"2013","unstructured":"Dalmady S , KissM, KepiroLet al. Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris. Clin. Dev. Immunol.474028 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535370213506435"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12371752"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.1.505"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073932"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061308"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0257-3"},{"issue":"1","key":"e_1_3_4_28_1","first-page":"S10\u2013S4","article-title":"Biopathology of the synovial membrane in psoriatic arthritis","volume":"8","author":"Ca\u00f1ete JD.","year":"2012","unstructured":"Ca\u00f1ete JD. Biopathology of the synovial membrane in psoriatic arthritis. Reumatol.Clin.8(1), S10\u2013S4 (2012).","journal-title":"Reumatol.Clin."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30577"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2012.01813.x"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.11.7423"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.049"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.012"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108316"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.06.042"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2009.10.005"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.6.2818"},{"issue":"1","key":"e_1_3_4_38_1","first-page":"22","article-title":"High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis","volume":"27","author":"Antonelli A","year":"2009","unstructured":"Antonelli A , FallahiP, Delle SedieAet al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin. Exp. Rheumatol.27(1), 22\u201327 (2009).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.010"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-076364"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1864"},{"issue":"2","key":"e_1_3_4_42_1","first-page":"374","article-title":"Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity?","volume":"34","author":"Candia L","year":"2007","unstructured":"Candia L , MarquezJ, HernandezCet al. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J. Rheumatol. 34(2), 374\u2013379 (2007).","journal-title":"J. Rheumatol."},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel229"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.5603\/FHC.2012.0010"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000041"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.04.013"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1159\/000316171"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111242"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201308"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket296"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200802"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-012-8303-5"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1586\/14789450.5.6.755"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.099549"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq105"},{"issue":"5","key":"e_1_3_4_56_1","first-page":"785","article-title":"Proteomic analysis of psoriatic skin tissue for identification of differentially expressed proteins: up-regulation of GSTP1, SFN and PRDX2 in psoriatic skin","volume":"28","author":"Ryu J","year":"2011","unstructured":"Ryu J , ParkSG, ParkBCet al. Proteomic analysis of psoriatic skin tissue for identification of differentially expressed proteins: up-regulation of GSTP1, SFN and PRDX2 in psoriatic skin. Int. J. Mol. Cell. Med.28(5), 785\u2013792 (2011).","journal-title":"Int. J. Mol. Cell. Med."},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2001.tb00152.x"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-4-41"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0321-7"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(00)00120-1"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076292"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1605"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1162"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI34916"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38026"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036658"},{"key":"e_1_3_4_67_1","unstructured":"US FDA. Rheumathology Therapeutics: Drugs and Biologics. www.fda.gov."},{"key":"e_1_3_4_68_1","unstructured":"European Medicine Agency \u2013 European public assessment reports (EPAR) for human medicines (keyword search for \u2018Psoriatic arthritis\u2019. www.ema.europa.eu."},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0025-6"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34627"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082925"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204741"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201897"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1504-5"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"e_1_3_4_77_1","unstructured":"European Medicines Agency: Leflunomide: European Public Assessment Reports (EPAR) \u2013 Scientific Discussion. www.ema.europa.eu."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21848"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120922"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2534-x"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804351"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.050"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-26"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121162"},{"key":"e_1_3_4_86_1","unstructured":"STELARA\u00ae. www.STELARAinfo.com."},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R200029200"},{"key":"e_1_3_4_89_1","unstructured":"ClinicalTrials.gov. http:\/\/clinicaltrials.gov."},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03325637"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.10.002"}],"container-title":["Biomarkers in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/bmm.14.76","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:29:54Z","timestamp":1746307794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/bmm.14.76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,18]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.2217\/bmm.14.76"],"URL":"https:\/\/doi.org\/10.2217\/bmm.14.76","relation":{},"ISSN":["1752-0363","1752-0371"],"issn-type":[{"type":"print","value":"1752-0363"},{"type":"electronic","value":"1752-0371"}],"subject":[],"published":{"date-parts":[[2014,7,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibmm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibmm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}